Department of Pathology, Hematological Malignancies Program, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, 38105, TN, USA.
Department of Pathology, Hematological Malignancies Program, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 342, Memphis, 38105, TN, USA.
Best Pract Res Clin Haematol. 2020 Sep;33(3):101193. doi: 10.1016/j.beha.2020.101193. Epub 2020 Jun 7.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a main cause of death in children despite recent improvements in cure rates. In the past decade, development of massively parallel sequencing has enabled large scale genome profiling studies of ALL, which not only led to identification of new subtypes in both B-cell precursor ALL (BCP-ALL) and T-cell ALL (T-ALL), but has also identified potential new therapeutic approaches to target vulnerabilities of many subtypes. Several of these approaches have been validated in preclinical models and are now being formally evaluated in prospective clinical trials. In this review, we provide an overview of the recent advances in our knowledge of genomic bases of BCP-ALL, T-ALL, and relapsed ALL, and discuss their clinical implications.
急性淋巴细胞白血病（ALL）是最常见的儿童癌症，尽管近年来治愈率有所提高，但仍是儿童死亡的主要原因。在过去的十年中，大规模平行测序的发展使 ALL 的大规模基因组分析研究成为可能，这不仅导致了 B 细胞前体 ALL（BCP-ALL）和 T 细胞 ALL（T-ALL）中新亚型的鉴定，而且还确定了针对许多亚型弱点的潜在新治疗方法。其中一些方法已在临床前模型中得到验证，现在正在前瞻性临床试验中进行正式评估。在这篇综述中，我们概述了我们对 BCP-ALL、T-ALL 和复发 ALL 基因组基础的最新认识，并讨论了它们的临床意义。
